about
Interventions for periodontal disease in people with rheumatoid arthritisTRPC channel activation by extracellular thioredoxinEfficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsRelationship between Periodontitis and Rheumatoid Arthritis: Review of the LiteratureMonoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitorsEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateThe cytokine model of schizophrenia: emerging therapeutic strategiesThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesPerceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe.Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).Rheumatoid arthritis: a role for immunosenescence?Dietary Phytochemicals: Natural Swords Combating Inflammation and Oxidation-Mediated Degenerative DiseasesRefining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabNitric oxide-driven hypoxia initiates synovial angiogenesis, hyperplasia and inflammatory lesions in miceCost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in chinaHerbal formula Xian-Fang-Huo-Ming-Yin regulates differentiation of lymphocytes and production of pro-inflammatory cytokines in collagen-induced arthritis miceRituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.[Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab.Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia.Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.Managing the drug treatment of rheumatoid arthritis.Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species.Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.Genetic evidence for involvement of neuronally expressed S1P₁ receptor in nociceptor sensitization and inflammatory pain.Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.Animal models of rheumatoid pain: experimental systems and insights.Impact of Schistosoma japonicum infection on collagen-induced arthritis in DBA/1 mice: a murine model of human rheumatoid arthritisEffectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsComparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial.Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era.Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
P2860
Q24200961-5DDA93C2-2599-421E-B1BF-7FC34DBF3689Q24650851-143C6306-41E6-42CF-979A-C6B2DC4C50F3Q24658506-1D6802B5-4E00-4300-A181-7CA0173A5BB3Q26741541-7C7D07D4-B7B1-4AA4-B15A-8E24B5C77366Q26782983-8C7DC626-7026-44A3-AC1D-0360D7CBFA40Q26824970-BCF4DED3-54B0-4157-96EC-BF429B26DD95Q26859134-70FF0E79-80F7-4DC6-B1E4-B8151FC20085Q26865996-82FAB359-B847-41ED-A699-5DD1BAD6D98BQ27022645-B415E7CA-452A-4685-8216-91BDCBA08453Q27335007-1821DAE2-622C-420F-A522-1581AD9B0FFBQ27335031-C684BA8D-048E-40A2-BD31-5BA32B73D49FQ27693905-A3C38984-02CA-414A-AFB4-462E32FCD43AQ28067382-63CFF951-480C-4F63-91E3-D25B96907E26Q28080677-9AD5DD0A-1585-4AA3-94C8-0E331F51EB73Q28482073-B686E0C6-F340-420A-9DE5-20B77603E81BQ28484306-F1C6D1E9-900B-40EB-BA5F-3D6F4EFA1F04Q28817934-52ED2D2A-781A-434E-9972-77E702314D04Q30250242-FA67E3EE-A254-4857-BF6A-893824E99894Q30572825-0C66C648-5774-4E72-8F3E-B5777003F4E0Q31090628-41E3070E-EC55-4D41-9C6F-E04B5B167C23Q33382447-F58CD5F2-2652-48B4-9E92-4A54B0637915Q33400381-DC8C08A0-A682-43D0-9862-0A46D071880CQ33504871-091C98EA-BD20-4026-8507-26AEB23D43B6Q33511764-50E54CC7-8CB1-4C91-B3AD-45569C4686CAQ33611369-6DDD89F9-BD68-460F-934C-651E0A11135EQ33654202-B83141B0-9476-4973-84BB-A811B8636786Q33658743-B3A41BB3-E3EC-40B7-9A99-EE4F4A2ACE8EQ33778590-88F683AE-EF33-473D-A093-3FBB665C437CQ33781056-41DB389C-A290-4455-BB66-012900273BF1Q33791993-8FBB8C79-E8B3-4C37-9B7A-4863C342A749Q33831886-7C3EDEDC-DF1A-4783-BE58-A5A69A210E1EQ33855714-F8231A5C-6403-48AA-A5D5-1F2020F6E565Q33859026-3041CB2A-6AAC-464F-90A1-03276D352F9DQ33999639-10ACC104-79AE-4C73-BC6F-D99037361ED6Q34012929-1542C3F8-E88C-4599-9125-4ABD146B04EFQ34033218-A52A5A41-4F76-4C62-B296-EE8C1A8E23ACQ34110066-CA31FFB0-8C50-41F1-B24E-61EEEFD069B4Q34124686-7B75522F-FA18-4242-994B-4FF9D2FFEF7BQ34168792-24C16252-2782-4166-8A9B-B1B0607CAA42Q34183220-6DBDC3A9-8448-4258-B202-E28B09DCCBE7
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
New therapies for treatment of rheumatoid arthritis.
@en
New therapies for treatment of rheumatoid arthritis.
@en-gb
type
label
New therapies for treatment of rheumatoid arthritis.
@en
New therapies for treatment of rheumatoid arthritis.
@en-gb
prefLabel
New therapies for treatment of rheumatoid arthritis.
@en
New therapies for treatment of rheumatoid arthritis.
@en-gb
P2093
P1433
P1476
New therapies for treatment of rheumatoid arthritis.
@en
P2093
Daniel Aletaha
Marcus Koeller
Michael H Weisman
P304
P356
10.1016/S0140-6736(07)60784-3
P407
P577
2007-12-01T00:00:00Z